Comparative Pharmacology
Head-to-head clinical analysis: MEZLIN versus PFIZERPEN G.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEZLIN versus PFIZERPEN G.
MEZLIN vs PFIZERPEN G
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mezlocillin is a ureidopenicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically inhibiting transpeptidase activity, leading to cell lysis.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and autolysin inhibition.
3-4 g intravenously every 4-6 hours; maximum 24 g/day.
2-4 million units (1.2-2.4 g) IV every 4-6 hours; maximum 24 million units per day.
None Documented
None Documented
Terminal elimination half-life is 0.7-1.2 hours in healthy adults; prolonged to 2-5 hours in renal impairment (CrCl <20 mL/min) and up to 10-20 hours in ESRD.
Terminal elimination half-life is 30-60 minutes in patients with normal renal function; prolonged to 2-10 hours in renal impairment (CrCl <10 mL/min).
Renal (70-80% unchanged via glomerular filtration and tubular secretion); biliary (approximately 2-3%); fecal (minor).
Primarily renal excretion via glomerular filtration and tubular secretion; 60-90% of dose excreted unchanged in urine within 6 hours. Biliary excretion accounts for less than 10%.
Category C
Category C
Antibiotic (Penicillin)
Antibiotic (Penicillin)